Treatment News : Hepatitis B Increases Risk of Death for Those Coinfected With Hep C and HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 2, 2013

Hepatitis B Increases Risk of Death for Those Coinfected With Hep C and HIV

Hepatitis B virus (HBV) infection raises the risk of death by 75 percent for those who are also coinfected with hepatitis C virus (HCV) and HIV, aidsmap reports. Shedding light on the poorly understood cross section between these three viruses, researchers from the Spanish VACH cohort studied 6,342 people coinfected with HIV and hep C in order to ascertain the risk of mortality associated with hep B infection.

Six percent of the cohort was triple infected with hep B, C and HIV. Among the entire cohort, there were 543 deaths across 26,000 person-years of follow-up, yielding a mortality rate of 2.1 deaths per 100 person years. A first round of analysis showed that hep B infection increased the risk of death by 90 percent among those coinfected with hep C and HIV. After factoring out other variables that affected mortality risk, including prior AIDS-defining illness, age, HIV and hep C treatment histories, CD4 count and viral load, the researchers concluded that hep B increased the risk of death by about 75 percent.

Those variables associated with a lowered risk of mortality included a higher CD4 count, treatment for HIV and hep C, and treatment with Viread (tenofovir, which is included in Truvada, Atripla and Complera), which acts against HIV as well as hep B.

To read the aidsmap report, click here.

To read the study abstract, click here.

Search: HIV, hepatitis B, hepatitis C, risk of death, mortality, coinfection, Spanish VACH cohort, CD4 count, viral load, Viread, tenofovir, Truvada, Atripla, Complera, aidsmap.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.